Switch Therapeutics was founded in 2020 to develop therapeutic applications from RNAi research conducted at Caltech, Harvard Medical School and City of Hope. In early 2022, Switch Therapeutics moved out of MBC Biolabs, an incubator facility, and into its own facility in South San Francisco and upon raising $52M of financing, publicly announced its launch.
Who We Are
At Switch, we are committed to revolutionizing the field of RNAi. Realizing the promise of our CASi platform requires a talented and diverse team. We are a dedicated group of scientifically curious individuals that work each and every day to help deliver transformational medicines that can dramatically improve patients’ lives.